The Michael J. Fox Foundation recently launched the Parkinson’s Progression Markers Initiative (PPMI), a landmark clinical study to identify and validate Parkinson’s disease biomarkers.
PPMI will be carried out in 18 sites in the United States and Europe. The study is testing today’s most promising biomarker candidates and, if successful in identifying a PD biomarker, could allow scientists to predict, objectively diagnose and monitor PD as well as definitively determine which medications work and which will not. The study will track 400 people newly diagnosed with PD and 200 who do not have the disease. Recruitment of study volunteers is now under way at eleven sites, with all sites expected to be recruiting by year-end.
To learn more, visit http://www.michaeljfox.org/PPMI.